101P Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
Harpreet Wasan(Hammersmith Hospital), Shubham Pant(The University of Texas MD Anderson Cancer Center), Hui‐Chuan Sun(Fudan University), J-P. Metges(Centre Hospitalier Régional Universitaire de Brest), Jennifer Ma(Jackson Memorial Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Jee Woo Kim(Seoul National University Bundang Hospital), Hongjo Choi(International Tuberculosis Research Center), James J. Harding(Memorial Sloan Kettering Cancer Center), E.Y. Chen(Oregon Health & Science University), Teresa Macarulla(Vall d'Hebron Hospital Universitari), John Bridgewater(University College London Hospitals NHS Foundation Trust), Michel Ducreux(Université Paris-Saclay), Jia Fan(Nanjing Tech University), Feng Xie(Qingdao University), H.-M. Chang(Ulsan College), D-Y. Oh(Seoul National University Hospital), Phillip M. Garfin(Zymeworks (Canada)), L. Bao(Hubei Cancer Hospital), Mohamedtaki Abdulaziz Tejani(AdventHealth Orlando)
Cited by 2
Related Papers
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k